April 17 (Reuters) – Belgian biopharmaceutical group UCB said on Friday it will acquire U.S.-based Neurona Therapeutics for up to $1.15 billion in a deal that will strengthen its epilepsy portfolio.
UCB will shell out $650 million upfront and up to $500 million in potential future milestone payments for privately held Neurona, the company said.
Neurona is a clinical-stage biotherapeutics firm whose investors include Fidelity and Schroders Capital, among others.
The deal is expected to close by the end of the second quarter of 2026.
Meanwhile, UCB added that while its 2026 revenue guidance remains unchanged, it now expects annual adjusted EBITDA to grow in the high-single‑digit to mid‑teens percentage.
(Reporting by Gursimran Kaur in Bengaluru; Editing by Shinjini Ganguli and Jonathan Ananda)
